Related references
Note: Only part of the references are listed.Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma
Mark Roschewski et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)
Pau Abrisqueta et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor
Kerry A. Rogers et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy.
Matthew Steven Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Share Paper
